Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of lenalidomide and to see how
well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related
Kaposi sarcoma (KS). Lenalidomide may stop the growth of tumor cells by blocking blood flow
to the tumor.